1242137-18-3 Usage
Description
4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-2,4-dioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide, also known as Oxo-MDV 3100, is an impurity of Enzalutamide (M199800). It is a complex organic compound with a unique chemical structure that plays a significant role in the pharmaceutical industry due to its association with Enzalutamide.
Uses
Used in Pharmaceutical Industry:
4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-2,4-dioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide is used as an impurity in the production of Enzalutamide, an androgen-receptor antagonist. Enzalutamide blocks androgens from binding to the androgen receptor, preventing nuclear translocation and co-activator recruitment of the ligand-receptor complex. This action leads to the induction of tumor cell apoptosis and is particularly useful in the treatment of castration-resistant prostate cancer.
In the development and manufacturing process of Enzalutamide, the presence of Oxo-MDV 3100 as an impurity is crucial for quality control and ensuring the safety and efficacy of the final drug product. The management and control of impurities like Oxo-MDV 3100 are essential to meet regulatory standards and maintain the therapeutic benefits of Enzalutamide for patients suffering from castration-resistant prostate cancer.
Check Digit Verification of cas no
The CAS Registry Mumber 1242137-18-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,4,2,1,3 and 7 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1242137-18:
(9*1)+(8*2)+(7*4)+(6*2)+(5*1)+(4*3)+(3*7)+(2*1)+(1*8)=113
113 % 10 = 3
So 1242137-18-3 is a valid CAS Registry Number.
1242137-18-3Relevant articles and documents
Copper-Mediated N-Arylations of Hydantoins
Thilmany, Pierre,Gérard, Phidéline,Vanoost, Agathe,Deldaele, Christopher,Petit, Laurent,Evano, Gwilherm
, p. 392 - 400 (2018/12/11)
A set of two broadly applicable procedures for the N-arylation of hydantoins is reported. The first one relies on the use of stoichiometric copper(I) oxide under ligand- A nd base-free conditions and enables a clean regioselective arylation at the N3 nitrogen atom, while the second one is based on the use of catalytic copper(I) iodide and trans-N,N′-dimethylcyclohexane-1,2-diamine and promotes arylation at the N1 nitrogen atom. Importantly, the combination of these two procedures affords a straightforward entry to diarylated hydantoins.
SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS
-
Page/Page column 35-36, (2010/09/17)
Compositions, such as pharmaceutical compositions, comprising specific diarylhydantoin and diarylthiohydantoin compounds, or salts or solvates thereof, are provided. Isolated and purified forms of the compounds are also described, as are unit dosage forms, compositions of substantially pure compound and kits comprising the compounds. The compounds and pharmaceutical compositions thereof may find use in the prevention and/or treatment of a variety of conditions, including prostate cancer, Parkinson's disease, Alzheimer's disease, and others.
